On July 8, 2015, Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD. "Trading on Nasdaq is a pivotal corporate milestone that will help raise the visibility of our therapeutic endeavors and increase the appeal of our shares to mutual funds, pension funds, and other institutional investors that may have previously been restricted from trading our shares," stated Jim Joyce, Chairman and CEO of Aethlon Medical. Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The company’s lead therapeutic candidate is the Aethlon Hemopurifier® (image), a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. The company also provides government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Also of note is that the start-up company Exosome Science, Inc. (ESI), is a wholly-owned subsidiary of Aethlon Medical, Inc. ESI creates diagnostic tools to detect and quantify the presence of exosomes in blood and other fluids.
Login Or Register To Read Full Story